Discover how a Sponsor optimized the drug delivery via IDDI’s Proposition of a Predictive Drug Supply Model
PLEASE FILL IN THE FORM TO ACCESS THE CASE STUDY
SITUATION:
- Phase II
- Efficacy assessment of a new drug in combination with an antibody in patients with advanced triple negative breast cancer
- Expensive drug to manufacture
- Different compositions for both Placebo and Active drugs:
- 5 mg vials
- 3 mg vials
- 2 mg vialsIn case of an event, drug dose reduction occurs
- Difficult to predict 3 mg and 2 mg drug allocations
- Usage of central pharmacies
SPONSOR’S REQUEST:
Optimize the drug delivery (limit the quantity of shipped vials yet assure sufficient vials are on site).